These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
34. Valvular heart disease in Parkinson's disease treated with ergot derivative dopamine agonists. Kim JY; Chung EJ; Park SW; Lee WY Mov Disord; 2006 Aug; 21(8):1261-4. PubMed ID: 16685692 [TBL] [Abstract][Full Text] [Related]
35. Risk of cardiac valvulopathy with use of bisphosphonates: a population-based, multi-country case-control study. Coloma PM; de Ridder M; Bezemer I; Herings RM; Gini R; Pecchioli S; Scotti L; Rijnbeek P; Mosseveld M; van der Lei J; Trifirò G; Sturkenboom M; Osteoporos Int; 2016 May; 27(5):1857-67. PubMed ID: 26694594 [TBL] [Abstract][Full Text] [Related]
36. Valvular heart disease and the use of dopamine agonists for Parkinson's disease. Zanettini R; Antonini A; Gatto G; Gentile R; Tesei S; Pezzoli G N Engl J Med; 2007 Jan; 356(1):39-46. PubMed ID: 17202454 [TBL] [Abstract][Full Text] [Related]
37. The mechanobiology of drug-induced cardiac valve disease. Lam NT; Balachandran K J Long Term Eff Med Implants; 2015; 25(1-2):27-40. PubMed ID: 25955005 [TBL] [Abstract][Full Text] [Related]
38. Dopamine agonists and cardiac valvulopathy in Parkinson disease: a case-control study. Senol MG; Togrol RE Neurology; 2007 Jul; 69(1):117; author reply 117-8. PubMed ID: 17606893 [No Abstract] [Full Text] [Related]
39. 5-HT Chaturvedi S; Misra DP; Prasad N; Rastogi K; Singh H; Rai MK; Agarwal V Int J Rheum Dis; 2018 Dec; 21(12):2128-2138. PubMed ID: 30207074 [TBL] [Abstract][Full Text] [Related]